BLOG

 

“I’ve heard that an ingredient called retortide is generating a lot of buzz, but it’s still in the clinical trial phase.” “I’m curious to know when it will actually become available.” — The more closely you follow GLP-1-related news, the more likely you are to have questions like these.

 

While positive economic figures are flying around on social media and in international media, I get the sense that the fundamental question—“So, what phase are we actually in right now?”—hasn’t been properly addressed.

 

To clarify from the outset, as of 2026, letartolide is not yet an officially approved drug in Japan or abroad; it is a compound currently in the final stages of large-scale clinical trials—in other words, in the “late stages of research.”

 

Positive results regarding weight management have been reported in multiple trials, and the developer is said to be preparing to submit an application for approval; however, it has not yet been determined when or in what form the product will actually become available.

 

In this article, we will outline the basics of the clinical trial system, the current status of retatortide, and key points to keep in mind when assessing its future prospects.

[Doctor’s Point]

When it comes to clinical trials, it’s easy for the impact of the numbers to take on a life of its own.

 

When I see reports like “I lost weight with 〇%,” I completely understand how easy it is to imagine that happening to me and get my hopes up.

 

However, from my perspective as someone who tracks information in the field, I feel it’s important to remember that clinical trial data represents “results for a group of participants who met specific criteria” and does not guarantee individual outcomes.

 

Knowing the numbers isn't a bad thing in itself, but I actually think it's much more important to know how to maintain a healthy distance from them.

How Do “Clinical Trials” Work in the First Place?

A clinical trial is a study conducted to verify the efficacy and safety of a new drug before it is actually used in humans.

 

Generally, clinical trials proceed through several phases, starting with the early stages—where safety is assessed in small groups—and progressing to the later stages, where efficacy and side effects are examined in detail among larger groups of participants. As the trial approaches its final stages, the number of participants increases, and data is collected under conditions that more closely resemble real-world use.

 

Retortide has already completed several large-scale clinical trial programs at this final stage and, from a development perspective, is at a “fairly advanced stage.”

 

However, it is important to understand that positive results from a clinical trial do not automatically guarantee approval or market launch. An application must be submitted to the regulatory authorities based on the trial results, and only after those authorities have re-evaluated the drug’s efficacy, safety, and manufacturing quality will the approval process begin.

 

In other words, positive clinical trial results are merely “the basis for moving on to the next phase” and do not constitute a “decision to approve” in and of themselves.

Key Perspectives to Keep in Mind When Reviewing Clinical Trial Data

News reports on clinical trials often highlight specific figures, such as “weight loss in the 〇% group,” and these tend to generate a lot of buzz due to their strong impact. However, there are several points to keep in mind when interpreting these figures.

 

First, since the characteristics of the participants in each study—such as age group, presence or absence of pre-existing conditions, and the dosage and duration of treatment—vary, it is not possible to simply compare all the figures side by side. Furthermore, behind the figures reported as averages lies a wide range of variation, with some participants showing significant changes and others showing little to no change.

 

Furthermore, conditions may differ between the controlled environment of a clinical trial and real-life use. Rather than being overly captivated by eye-catching statistics, keeping in mind “what kind of group these results come from and under what conditions they were obtained” as you follow the news will lead to a more realistic understanding.

What stage are the clinical trials for letatolide currently in?

A series of Phase 3 trials (the final stage of clinical trials) for letroctide, known as “TRIUMPH,” is currently underway, and results from several of these trials have been released from late 2025 through 2026. Here, we present the specific details as reported in the media.

 

First, in the TRIUMPH-1 trial, after 104 weeks (approximately 2 years) of continuous administration, an average weight loss of approximately 301 TP3T was reported in the highest-dose group. This result is often cited as a significant figure in trials of drugs intended for weight loss.

 

Furthermore, in the TRIUMPH-4 trial, two doses—9 mg and 12 mg—were administered for 68 weeks; an average weight loss of 28.71 TP3T was reported in the 12 mg group, while the 9 mg group showed an average weight loss of 26.41 TP3T; in contrast, the placebo group, which did not contain the active ingredient, showed a weight loss of only 2.11 TP3T. This trial also assessed knee pain; pain scores improved by an average of approximately 761 TP3T in the treatment groups, and at week 68, more than 121 TP3T of participants reported experiencing almost no knee pain, whereas in the placebo group, that proportion was reported to be 4.21 TP3T.

 

Furthermore, in the TRIUMPH-2 and TRIUMPH-3 trials—which focused on participants with pre-existing conditions such as type 2 diabetes and cardiovascular disease—average weight losses of approximately 211 TP3T and 231 TP3T, respectively, were reported at the 80-week mark. The fact that significant changes have been reported even among participants with pre-existing conditions is one of the key points drawing attention.

 

These figures are all average reports from specific groups that participated in clinical trials, and the conditions and treatment durations vary from trial to trial. If you focus solely on the statement that “on average, significant weight loss was observed,” it might seem as though this happens to everyone in the same way; however, in reality, many factors—such as age, body type, and lifestyle—influence the results. When looking at these figures, it is important to consider the underlying study design as well.

 

In terms of safety, gastrointestinal symptoms such as nausea, diarrhea, and constipation were reported more frequently in this group than in the placebo group. In addition, there are reports that symptoms related to skin sensation (known as dysesthesia) were observed in approximately 201 to 300 participants in the highest-dose group. While most cases were mild and few led to discontinuation of treatment, it remains true that the occurrence and perception of side effects vary from person to person.

Timeline for Approval and What You Need to Know Now

It has been reported that Eli Lilly, the drug’s developer, plans to submit an application for approval to U.S. regulatory authorities around the first quarter of 2027 (approximately January through March), based on these trial results. One reason cited for this timeline is that it is taking time to compile data related to manufacturing and quality control.

 

However, this is merely an estimate of the timing of the application and does not indicate when approval itself will be granted. From the time of application to actual approval and the point at which the product becomes available for use in Japan, there are typically several stages of review and procedures, and this process takes a considerable amount of time. At this point, there is no information that allows us to definitively state “when it will become available,” so it is best to monitor developments on the assumption that the outlook may change in the future depending on the timing of the application and the progress of the review process.

 

Although retortide is still in the pre-approval stage, it is already being used by many people in Europe and the United States, and is drawing attention for its effectiveness and minimal side effects. BIANCA Clinic was also among the first to begin offering Letortide, and it is starting to gain popularity among patients who expect it to be more effective than Manjaro, as well as those who were unable to use Manjaro due to side effects such as hair loss and nausea.

How to Approach Information on Clinical Trials

For those who regularly follow international clinical trial news, progress on retatolcid will likely remain a topic of interest. Rather than getting carried away with every new piece of information, some people may prefer to take a more measured approach—acknowledging that the drug is “still in the research phase” and gradually gathering information—while others may want to try an option right away, without waiting for approval.

 

For those who, like the latter group, wish to begin considering treatment now without waiting for approval, BIANCA Clinic already offers retatrolide as a self-pay service. Since this remains an unapproved ingredient in Japan, we will carefully explain the sourcing process, safety information from overseas, and the availability of other approved alternatives in Japan during your consultation. We will then work with you to determine whether it is suitable for your physical condition and preferences. Rather than making a decision based solely on statistics, we encourage you to explore your options through dialogue with a specialist.

 

Of course, the decision to wait for letrozole’s approval is by no means a bad one. There are still unknowns regarding this new ingredient, so the approach of wanting to wait until more data has been accumulated before making a decision is entirely reasonable.

 

Whether you prioritize the desire to “try it right away” or the caution to “wait until more information becomes available” depends on your personal values and disposition.

Frequently Asked Questions

If you're interested, please come in for a consultation to learn more.

Information regarding clinical trials for letrozole is a topic that will continue to be updated. If you focus solely on statistics and news reports, it may actually become harder to see what is a realistic option for you.

 

At Ginza Bianca Clinic, in light of these clinical trial developments, we already offer retatolide as a self-pay treatment. During your consultation, we will carefully explain each detail—including the fact that this is an unapproved substance in Japan, its sourcing, safety information from overseas, and how it may interact with your individual constitution and pre-existing conditions. Even if you’re simply at the stage of thinking, “I’ve seen the news about the clinical trial, but I want to know if I can actually try it,” that’s perfectly fine. If you’re interested, please come in for a consultation.

 

I think it’s only natural to feel anxious when you’re overwhelmed by new information. If there’s anything you don’t understand or any news reports that concern you, please don’t hesitate to ask me during your appointment. Let’s work together to figure out the best way of thinking for you right now.

 

▷ Counseling Appointment Page